Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]

EY Yu; JM Piulats; G Gravis; PCC Fong; T Todenhofer; B Laguerre; JA Arranz; S Oudard; C Massard; J Heinzelbecker; LT Nordquist; J Carles; MP Kolinsky; Marinela Augustin; H Gurney; A Tafreshi; XT Li; P Qiu; CH Poehlein; C Schloss; JS de Bono

doi:10.1016/j.eururo.2022.11.025

Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]

EY Yu, JM Piulats, G Gravis, PCC Fong, T Todenhofer, B Laguerre, JA Arranz, S Oudard, C Massard, J Heinzelbecker, LT Nordquist, J Carles, MP Kolinsky, Marinela Augustin (Co-Autor/-in), H Gurney, A Tafreshi, XT Li, P Qiu, CH Poehlein, C SchlossJS de Bono

Universitätsklinik für Innere Medizin 5 - Onkologie und Hämatologie

Publikation: Beitrag in Fachzeitschrift › Korrektur › Begutachtung

3 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	e87
Fachzeitschrift	EUROPEAN UROLOGY
Jahrgang	83
Ausgabenummer	3
DOIs	https://doi.org/10.1016/j.eururo.2022.11.025
Publikationsstatus	Veröffentlicht - März 2023

Zugriff auf Dokument

10.1016/j.eururo.2022.11.025

3 Zitationen
1 Originalarbeit (Zeitschrift)

Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
Yu, E., Piulats, J., Gravis, G., Fong, P., Todenhofer, T., Laguerre, B., Arranz, J., Oudard, S., Massard, C., Heinzelbecker, J., Nordquist, L., Carles, J., Kolinsky, M., Augustin, M. (Co-Autor/-in), Gurney, H., Tafreshi, A., Li, X., Qiu, P., Poehlein, C. & Schloss, C. &1 mehr, de Bono, J., Jan. 2023, in: EUROPEAN UROLOGY . 83, 1, S. 15-26 12 S.
Publikation: Beitrag in Fachzeitschrift › Originalarbeit (Zeitschrift) › Begutachtung
30 Quellenangaben (Web of Science)

Dieses zitieren

Yu, EY., Piulats, JM., Gravis, G., Fong, PCC., Todenhofer, T., Laguerre, B., Arranz, JA., Oudard, S., Massard, C., Heinzelbecker, J., Nordquist, LT., Carles, J., Kolinsky, MP., Augustin, M., Gurney, H., Tafreshi, A., Li, XT., Qiu, P., Poehlein, CH., ... de Bono, JS. (2023). Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]. EUROPEAN UROLOGY , 83(3), e87. https://doi.org/10.1016/j.eururo.2022.11.025

Yu, EY ; Piulats, JM ; Gravis, G et al. / Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer : Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]. in: EUROPEAN UROLOGY 2023 ; Jahrgang 83, Nr. 3. S. e87.

@article{cbc781f1645a46b2a82f3a103b0b3813,

title = "Corrigendum to {"}Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study{"} [Eur Urol 83 (2023) 15-26]",

author = "EY Yu and JM Piulats and G Gravis and PCC Fong and T Todenhofer and B Laguerre and JA Arranz and S Oudard and C Massard and J Heinzelbecker and LT Nordquist and J Carles and MP Kolinsky and Marinela Augustin and H Gurney and A Tafreshi and XT Li and P Qiu and CH Poehlein and C Schloss and {de Bono}, JS",

note = "Augustin: Paracelsus Medical University, Nuremberg, Germany",

year = "2023",

month = mar,

doi = "10.1016/j.eururo.2022.11.025",

language = "English",

volume = "83",

pages = "e87",

journal = "EUROPEAN UROLOGY ",

issn = "0302-2838",

number = "3",

}

Yu, EY, Piulats, JM, Gravis, G, Fong, PCC, Todenhofer, T, Laguerre, B, Arranz, JA, Oudard, S, Massard, C, Heinzelbecker, J, Nordquist, LT, Carles, J, Kolinsky, MP, Augustin, M, Gurney, H, Tafreshi, A, Li, XT, Qiu, P, Poehlein, CH, Schloss, C & de Bono, JS 2023, 'Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]', EUROPEAN UROLOGY , Jg. 83, Nr. 3, S. e87. https://doi.org/10.1016/j.eururo.2022.11.025

Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]. / Yu, EY; Piulats, JM; Gravis, G et al.
in: EUROPEAN UROLOGY , Jahrgang 83, Nr. 3, 03.2023, S. e87.

Publikation: Beitrag in Fachzeitschrift › Korrektur › Begutachtung

TY - JOUR

T1 - Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer

T2 - Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]

AU - Yu, EY

AU - Piulats, JM

AU - Gravis, G

AU - Fong, PCC

AU - Todenhofer, T

AU - Laguerre, B

AU - Arranz, JA

AU - Oudard, S

AU - Massard, C

AU - Heinzelbecker, J

AU - Nordquist, LT

AU - Carles, J

AU - Kolinsky, MP

AU - Augustin, Marinela

AU - Gurney, H

AU - Tafreshi, A

AU - Li, XT

AU - Qiu, P

AU - Poehlein, CH

AU - Schloss, C

AU - de Bono, JS

N1 - Augustin: Paracelsus Medical University, Nuremberg, Germany

PY - 2023/3

Y1 - 2023/3

U2 - 10.1016/j.eururo.2022.11.025

DO - 10.1016/j.eururo.2022.11.025

M3 - Correction

C2 - 36528479

SN - 0302-2838

VL - 83

SP - e87

JO - EUROPEAN UROLOGY

JF - EUROPEAN UROLOGY

IS - 3

ER -

Yu EY, Piulats JM, Gravis G, Fong PCC, Todenhofer T, Laguerre B et al. Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]. EUROPEAN UROLOGY . 2023 Mär;83(3):e87. doi: 10.1016/j.eururo.2022.11.025

Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]

Zugriff auf Dokument

Publikationen

Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study

Dieses zitieren